Company intelligence / Profile preview

Diabact

Uppsala, Sweden

Ownership: Private
Development stage: Other

Overview

Diabact AB was a Swedish company (Uppsala, founded 1995) developing novel drug delivery technologies and diagnostic products. Its main legacy is the development and launch of the Diabact® UBT diagnostic breath test (now owned/marketed by Kibion/Mayoly Spindler) and Rapinyl® for acute cancer pain (licensed to Kyowa Hakko).

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Kyowa Hakko (Japan, for Rapinyl® development and marketing)

Beyond the preview

Go deeper on Diabact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabact.

Explore the full profile